SOC Telemed to Announce Fourth Quarter 2020 Financial Results and Host Conference Call

PR Newswire

RESTON, Va., March 12, 2021 /PRNewswire/ — SOC Telemed (SOC) (Nasdaq: TLMD), the largest national provider of acute care telemedicine, today announced that the company will release results for its fourth quarter ended December 31, 2020 on Tuesday, March 30, 2021 after the market closes. In conjunction, the management team will host a conference call to review the results at 5:00 p.m. E.T. on the same day.

Conference Call Details
The conference call can be accessed by dialing 1-877-870-4263 for U.S. participants, or 1-412-317-0790 for international participants, and referencing the “SOC Telemed call”; or via a live audio webcast available on the Investor Relations section of the Company website at https://investors.soctelemed.com/ or https://www.webcaster4.com/Webcast/Page/2568/40293. A webcast replay will be available for on-demand listening shortly after the completion of the call at the same web link.

About SOC Telemed

SOC Telemed (SOC) is the largest national provider of telemedicine technology and solutions to hospitals, health systems, post-acute providers, physician networks, and value-based care organizations. Built on proven and scalable infrastructure as an enterprise-wide solution, SOC’s technology platform, Telemed IQ, rapidly deploys and seamlessly optimizes telemedicine programs across the continuum of care. SOC provides a supportive and dedicated partner presence, virtually delivering patient care through teleNeurology, telePsychiatry, teleICU, and telePulmonology, enabling healthcare organizations to build sustainable telemedicine programs in any clinical specialty. SOC enables organizations to enrich their care models and touch more lives by supplying healthcare teams with industry-leading solutions that drive improved clinical care, patient outcomes, and organizational health. The company was the first provider of acute clinical telemedicine services to earn The Joint Commission’s Gold Seal of Approval and has maintained that accreditation every year since inception. For more information, visit www.soctelemed.com.

Media Relations:

Lauren Shankman

Trevelino/Keller
[email protected]

Investor Relations:



Bob East or Jordan Kohnstam
Westwicke, an ICR company
[email protected]
(443) 213-0500

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/soc-telemed-to-announce-fourth-quarter-2020-financial-results-and-host-conference-call-301246239.html

SOURCE SOC Telemed

Harvest Health & Recreation Inc. To Hold Fourth Quarter and Full Year 2020 Earnings Conference Call on March 30, 2021

PR Newswire

PHOENIX, March 12, 2021 /PRNewswire/ — Harvest Health & Recreation Inc. (CSE: HARV, OTCQX: HRVSF) (“Harvest”), a vertically integrated cannabis company and multi-state operator in the U.S., today announced that it will hold a conference call on Tuesday, March 30, 2021 at 5:00 PM Eastern Time following the release of its fourth quarter and full year 2020 financial results.   

Participating on the call to review Harvest Health & Recreation’s Fourth Quarter and Full Year 2020 financial and operating results will be Steve White, Chief Executive Officer and Deborah Keeley, Chief Financial Officer.

Registration for this event is required. Please use this link to register:
http://www.directeventreg.com/registration/event/9090211

Following registration, an email confirmation will be sent including dial in details and unique conference call codes. Registration will remain open during the call however we recommend advance registration to access the event.    

Fourth quarter results will be available at:
https://investor.harvesthoc.com/financials/default.aspx

The live conference call webcast and replay will be available at:
https://investor.harvesthoc.com/financials/default.aspx


About Harvest Health & Recreation Inc.


Headquartered in Tempe, Arizona, Harvest Health & Recreation Inc. is a vertically integrated cannabis company and multi-state operator. Since 2011, Harvest has been committed to expanding its retail and wholesale presence throughout the U.S., acquiring, manufacturing, and selling cannabis products for patients and consumers in addition to providing services to retail dispensaries. Through organic license wins, service agreements, and targeted acquisitions, Harvest has assembled an operational footprint spanning multiple states in the U.S. Harvest’s mission is to improve lives through the goodness of cannabis. We hope you’ll join us on our journey:


https://harvesthoc.com


 

Facebook: 

@HarvestHOC


Instagram: 

@HarvestHOC


Twitter: 

@HarvestHOC

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/harvest-health–recreation-inc-to-hold-fourth-quarter-and-full-year-2020-earnings-conference-call-on-march-30-2021-301246175.html

SOURCE Harvest Health & Recreation Inc.

TZP Strategies Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing March 12, 2021

PR Newswire

New York, March 12, 2021 /PRNewswire/ — TZP Strategies Acquisition Corp. (NASDAQ: TZPSU) (the “Company”) announced that, commencing March 12, 2021, holders of the units sold in the Company’s initial public offering of 28,750,000 units, completed on January 22, 2021, may elect to separately trade the Class A ordinary shares and warrants included in the units. Any units not separated will continue to trade on the Nasdaq Capital Market (the “Nasdaq”) under the symbol “TZPSU,” and the separated Class A ordinary shares and warrants are expected to trade on the Nasdaq under the symbols “TZPS” and “TZPSW,” respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Unitholders will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into Class A ordinary shares and warrants.

The units were initially offered by the Company in an underwritten offering. Credit Suisse Securities (USA) LLC acted as book-running manager of the offering. A registration statement relating to the units and the underlying securities was declared effective by the Securities and Exchange Commission (the “SEC”) on January 19, 2021.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

This press release may include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as “anticipate,” “believe,” “estimate,” “expect,” “intend” and similar expressions identify forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus relating to the Company’s initial public offering filed with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact:

[email protected]

(212) 398-0300

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/tzp-strategies-acquisition-corp-announces-the-separate-trading-of-its-class-a-ordinary-shares-and-warrants-commencing-march-12-2021-301246172.html

SOURCE TZP Group

COMSovereign to Present at Investor Summit’s Q1 Virtual Summit on March 25, 2021

PR Newswire

DALLAS, March 12, 2021 /PRNewswire/ — COMSovereign Holding Corp. (NASDAQ: COMS) (“COMSovereign” or “Company”), a U.S.-based developer of 4G LTE Advanced and 5G Communication Systems and Solutions, announced its presentation at the Q1 Virtual Summit hosted by the Investor Summit Group scheduled to take place on March 23-25, 2021.

COMSovereign Chairman and Chief Executive Officer Dan Hodges will host a virtual presentation during the conference and participate in one-on-one meetings where he will discuss the Company’s position as an all-American provider of critical 4G LTE/5G wireless infrastructure solutions, its full range of complementary product offerings for public and private telecom networks, and its growing portfolio of intellectual property. Mr. Hodges will also discuss recent milestones including acquisitions, the ramp up of its domestic manufacturing and its expanded management team.

To access the call, please use the following information:


Investor Summit:


Q1 Virtual Summit

Date:

March 25, 2021

Presentation Time:

1:00 pm ET (10:00 am Pacific time)

Webcast:


https://zoom.us/webinar/register/WN_ieg6BdR4QoiWUeXMRRiG6g

Format: 

Virtual presentation and 1×1’s

Speaker:

Dan Hodges, Chairman and Chief Executive Officer

Conference website here

 

For more information on the Q1 Virtual Summit or to schedule a one-on-one meeting with COMSovereign management, please contact your conference representative or you may also email your request to [email protected] or call Chris Tyson at (949) 491-8235.

For more information about COMSovereign, please visit www.COMSovereign.com and connect with us on Facebook and Twitter.

About COMSovereign Holding Corp.
COMSovereign Holding Corp. (Nasdaq: COMS) has assembled a portfolio of communications technology companies that enhance connectivity across the entire data transmission spectrum. Through strategic acquisitions and organic research and development efforts, COMSovereign has become a U.S.-based communications provider able to provide 4G LTE Advanced and 5G-NR telecom solutions to network operators and enterprises. For more information about COMSovereign, please visit www.COMSovereign.com.

Contacts:

Steve Gersten, Director of Investor Relations
COMSovereign Holding Corp.
813-334-9745
[email protected]

External Investor Relations:

Chris Tyson, Executive Vice President
MZ Group – MZ North America
949-491-8235
[email protected]
www.mzgroup.us

and

Media Relations for COMSovereign Holding Corp.:

Michael Glickman

MWGCO, Inc.
917-397-2272
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/comsovereign-to-present-at-investor-summits-q1-virtual-summit-on-march-25-2021-301246166.html

SOURCE COMSovereign Holding Corp.

Advaxis to Present at the American Association for Cancer Research (AACR) 2021 Annual Meeting

PRINCETON, N.J., March 12, 2021 (GLOBE NEWSWIRE) — Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and Precision for Medicine, a specialized services company supporting next generation approaches to drug development and commercialization, today announce that they will present data on a) the development of a novel flow immunophenotyping assay to accurately evaluate total PD-1 expression as a pharmacodynamic biomarker during PD-1 blockade treatment with pembrolizumab and b) the correlation of changes in T cell populations with the clinical activity observed in the ongoing ADXS-503 clinical trial, in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021, taking place virtually from April 10-15, 2021.

Details on the posters and corresponding abstracts are shown below. All posters will be made available on the conference website on April 10, 2021.

Title: Evaluation of total PD-1 expression using multi-color flow cytometry in metastatic non-small cell lung cancer patients treated with multi-neoantigen vector (ADXS-503) alone and in combination of pembrolizumab to assess T-cell & T-cell memory subsets
Session Category: Immunology
Session Title: Immune Monitoring / Clinical Correlates
Abstract Number: 1671

The full text of the abstract is available on the AACR Annual Meeting 2021 website.

About Advaxis, Inc.

Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.

To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook and YouTube.

About Precision for Medicine

Precision for Medicine is the first biomarker-driven clinical research services organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies novel biomarker approaches to clinical research that integrate clinical trial execution with deep scientific knowledge, laboratory expertise and advanced data sciences. This convergence of trials, labs and data sciences is driving faster clinical development and approval. Precision for Medicine is part of Precision Medicine Group, with over 2,100 people in 35 locations in the U.S., Canada, and Europe. For more information, visit PrecisionForMedicine.com.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are any statements that express the current beliefs and expectations of management, including but not limited to statements related to the expected clinical development of the Company’s drug product candidates. These and other risks are discussed in the Company’s filings with the SEC, including, without limitation, its Annual Report on Form 10-K, filed on December 20, 2019 and Form 10-K/A on February 28, 2020, and its periodic reports on Form 10-Q and Form 8-K. Any statements contained herein that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements, which speak only as of the date they were made. The Company undertakes no obligation to update or revise forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA.

Contact:

Tim McCarthy, LifeSci Advisors, LLC
212.915.2564
[email protected] 



AT&T Provides Update on Strategy, Financial Outlook

AT&T Provides Update on Strategy, Financial Outlook

AT&T’s Analyst & Investor Day to be webcast at 10 a.m. ET today on the AT&T Investor Relations website

DALLAS–(BUSINESS WIRE)–AT&T* (NYSE:T) is providing an update on its strategy and financial outlook and will host a webcast today to discuss these plans. Company updates include:

  • 120-150 million HBO Max/HBO subscribers by 2025. AT&T expects between 120 million and 150 million worldwide HBO Max and HBO subscribers by the end of 2025, up from the 75-90 million projected in October 2019.1
    • HBO Max international expansion and AVOD launch in June. AT&T expects to launch HBO Max in 60 markets outside the United States in 2021 (39 territories in Latin America and the Caribbean in late June and 21 territories in Europe in the second half of 2021). Also in June, the company expects to launch in the U.S. market an advertising-supported (AVOD) version of HBO Max.
  • 3 million new fiber locations. In 2021, AT&T plans to increase its fiber footprint by an additional 3 million customer locations across more than 90 metro areas.
  • C-band spectrum deployment to begin in 2021. AT&T acquired 80 MHz of C-band spectrum in the FCC’s Spectrum Auction 107. The company plans to begin deploying the first 40 MHz of this spectrum by the end of 2021. AT&T expects to spend $6-8 billion in capex deploying C-band spectrum, with the vast majority of the spend occurring from 2022 to 2024. Expected C-band deployment costs are already included in the company’s 2021 capex guidance and in its leverage ratio target for 2024.
    • Funding C-band spectrum. AT&T’s investment in C-band spectrum via Auction 107 totals $27.4 billion, including expected payments of $23 billion in 2021.
    • To meet this commitment and other near-term priorities, in 2021 the company expects to have access to cash totaling at least $30 billion, including cash on hand at the end of 2020 of $9.7 billion,2 commercial paper issued in January 2021 of $6.1 billion and financing via a term loan credit agreement of $14.7 billion.
  • End-of-year 2021 debt ratio target of 3.0x. The company expects to end 2021 with a net debt-to-adjusted EBITDA ratio of about 3.0x,3 reflecting an anticipated increase in net debt of about $6 billion to fund the C-band spectrum purchase.
    • 2024 debt ratio of 2.5x or lower. During 2024, AT&T expects to reach a net debt-to-adjusted EBITDA ratio of 2.5x or lower.3 To achieve this target, the company expects to use all cash flows after total dividends to pay down debt and will continue to look for opportunities to monetize non-strategic assets. The company also does not plan to repurchase shares during this period.
  • 2021 guidance unchanged. AT&T’s 2021 financial guidance, announced in January 2021, is unchanged on a comparative basis. For the full year, the company continues to expect:
    • Consolidated revenue growth in the 1% range
    • Adjusted EPS to be stable with 20204,5
    • Gross capital investment6 in the $21 billion range, with capital expenditures in the $18 billion range
    • 2021 free cash flow7 in the $26 billion range, with a full-year total dividend payout ratio in the high 50’s% range.8

More details will be shared during the webcast, which will be available on the AT&T Investor Relations website beginning at 10 a.m. Eastern time today. Presenters will include: John Stankey, CEO; Jeff McElfresh, CEO-AT&T Communications; Jason Kilar, CEO-WarnerMedia; John Stephens, CFO and Pascal Desroches, incoming CFO. Related materials will also be posted to the website.

“We’re being deliberate and strategic with how we allocate capital to invest in our market focus areas of 5G, fiber and HBO Max, while being committed to sustaining the dividend at current levels and utilizing cash after dividends to reduce debt,” said John Stankey, AT&T CEO.

“Our number one priority in 2021 is growing our customer relationships. It’s about more than just adding to our customer base. It’s about expanding the growth opportunity in our three market focus areas and also increasing our share within each market,” Stankey said. “We’re focused on creating deeper relationships with our current customers to increase their daily engagement with our products and services, enabling us to gather more meaningful insights, drive loyalty, and stay ahead of their rapidly changing preferences. As demand for connectivity and content continues to grow, we are well positioned to deliver.”

Improved Revenue and EBITDA Trajectory

In the second half of 2021, AT&T expects to close its recently announced transaction to move its U.S. video business operations into a newly formed entity jointly owned with TPG Capital. Following close of the transaction, which is subject to customary closing conditions and regulatory reviews, AT&T expects to deconsolidate the U.S. video unit from its consolidated results. While the video business pressured the top line by about 100 basis points and EBITDA margin by about 300 basis points in 2020, AT&T does not expect the transaction to have a material impact on 2021 guidance due to the timing of close.

In the longer term, AT&T expects an increased focus on growth areas enabled by separating the U.S. video business will improve the trajectory of revenue growth and adjusted EBITDA growth for its remaining business going forward. The company anticipates these improvements will also be driven by expected trends in the business, including:

  • Wireless EBITDA growth from profitable share gains, customer growth and continued adoption of unlimited plans
  • Expansion of the fiber footprint and increased fiber penetration
  • Improved margins in the business wireline unit as the company continues to simplify the portfolio
  • Improvements at WarnerMedia as HBO Max scales, advertising gradually improves and cost savings from recent organization changes offset investment in HBO Max
  • Improvement in AT&T Latin America from customer growth and continued expense management

Strong Cash Position

Given its previously discussed cash position and access to cash, AT&T anticipates that it will have the flexibility to meet its 2021 financial commitments including:

  • The $23 billion in expected payments for C-Band spectrum
  • Dividends to shareholders of nearly $15 billion, subject to approval by the board of directors
  • Gross capital investment in the $21 billion range6
  • Continued repayment of debt

Broadband Connectivity

AT&T remains focused on growing connectivity within its wireless and fiber products. With its hybrid fixed and mobile network approach, the company is well positioned to meet the connectivity needs of all customer segments.

Fiber. Fiber is foundational to AT&T’s broadband portfolio. Customers have a need for reliable, robust symmetrical technology solutions like fiber, and the company continues to expand its fiber footprint to households and businesses in 90 metro areas across the United States. AT&T expects the 3 million additional fiber customer locations planned for 2021 will support continued momentum in its broadband business unit. In areas where AT&T has deployed its fiber network, the company has 10% higher market share than its competitors and about 70% of its gross adds are new to AT&T. In 2021, the company expects broadband revenue growth in the mid-single digits and expanding margins in its broadband business unit.

Strengthened spectrum position. Over the last four years, AT&T has more than doubled the spectrum deployed in its network, with 70% of its low and mid-band spectrum in service. As it deploys the remaining 30% of low and mid-band spectrum, the company expects further enhanced performance in the top 50 urban markets, which it believes will help support continued customer growth.

As previously discussed, AT&T expects to begin to deploy 40 MHz of its 80 MHz of C-band spectrum by the end of 2021. The company also expects millimeter wave spectrum to be a key part of its broader network densification strategy. AT&T continues to expect wireless service revenue growth in the 2% range with modest wireless EBITDA growth for full-year 2021.

Scaling HBO Max

In addition to its updated guidance for HBO Max and HBO subscribers by the end of 2025, AT&T further expects to end 2021 with between 67 and 70 million subscribers worldwide, up from about 61 million at the end of 2020.1

AT&T expects its Home Box Office business unit revenues to more than double over the next 5 years. As HBO Max scales at a global level, the company plans to increase investment, with expectations for peak dilution in 2022 and break even in 2025.

Subscriber and revenue growth in 2021 are expected to be partially driven by the initial international expansion of HBO Max and the launch of an advertising-supported version of HBO Max.

Tune into AT&T’s Analyst & Investor Day webcast at 10 a.m. Eastern time today. The webcast will be available on the AT&T Investor Relations website.

*About AT&T

AT&T Inc. (NYSE:T) is a diversified, global leader in telecommunications, media and entertainment, and technology. Consumers and businesses have more than 225 million monthly subscriptions to our services. AT&T Communications provides more than 100 million U.S. consumers with entertainment and communications experiences across TV, mobile and broadband. Plus, it serves high-speed, highly secure connectivity and smart solutions to nearly 3 million business customers. WarnerMedia is a leading media and entertainment company that creates and distributes premium and popular content to global audiences through its consumer brands, including: HBO, HBO Max, Warner Bros., TNT, TBS, truTV, CNN, DC Entertainment, New Line, Cartoon Network, Adult Swim and Turner Classic Movies. Xandr, now part of WarnerMedia, provides marketers with innovative and relevant advertising solutions for consumers around premium video content and digital advertising through its platform. AT&T Latin America provides pay-TV services across 10 countries and territories in Latin America and the Caribbean and wireless services to consumers and businesses in Mexico.

AT&T products and services are provided or offered by subsidiaries and affiliates of AT&T Inc. under the AT&T brand and not by AT&T Inc. Additional information is available at about.att.com.

© 2021 AT&T Intellectual Property. All rights reserved. AT&T, the Globe logo and other marks are trademarks and service marks of AT&T Intellectual Property and/or AT&T affiliated companies. All other marks contained herein are the property of their respective owners.

Cautionary Language Concerning Forward-Looking Statements

Information set forth in this news release contains financial estimates and other forward-looking statements that are subject to risks and uncertainties, and actual results might differ materially. A discussion of factors that may affect future results is contained in AT&T’s filings with the Securities and Exchange Commission. AT&T disclaims any obligation to update and revise statements contained in this news release based on new information or otherwise.

This news release may contain certain non-GAAP financial measures. Reconciliations between the non-GAAP financial measures and the GAAP financial measures are available on the company’s website at https://investors.att.com.


1 Worldwide HBO Max and HBO subscribers consist of domestic HBO Max subscribers and domestic and international HBO subscribers, and excludes free trials, basic and Cinemax subscribers. Domestic HBO Max and HBO subscribers consist of accounts with access to HBO Max (including wholesale subscribers that may not have signed in) and HBO accounts, and excludes free trials and Cinemax subscribers.

2 Cash and cash equivalents as of December 31, 2020.

3 Net debt-to-adjusted EBITDA ratios are non-GAAP financial measures that are frequently used by investors and credit rating agencies to provide relevant and useful information. Our net debt-to-adjusted EBITDA ratio is calculated by dividing the net debt by the sum of the most recent four quarters of adjusted EBITDA.

4 The company expects adjustments to 2021 reported diluted EPS to include merger-related amortization in the range of $4.3 billion and other adjustments, a non-cash mark-to-market benefit plan gain/loss, and other items. Expect the mark-to-market adjustment, which is driven by interest rates and investment returns that are not reasonably estimable at this time, to be a significant item. Our 2021 EPS depends on future levels of revenues and expenses which are not reasonably estimable at this time. Accordingly, we cannot provide a reconciliation between our non-GAAP metrics and the reported GAAP metrics without unreasonable effort.

5 As previously indicated, management expects a reduction of $300 million in depreciation and amortization expense each quarter until the DIRECTV transaction closes. Just under half the reduction reflects the fourth-quarter 2020 impairment taken on the business. The remainder of the reduction reflects the reclassification of the assets to “held for sale.” In addition, AT&T expects to update the lives of video and broadband customers used to recognize subscriber costs. In the first quarter of 2021, we estimate an increase in operating expenses of approximately $130 million due to this change.

6 Gross capital investment includes capital expenditures and cash payments for vendor financing and excludes FirstNet reimbursements. In 2021, vendor financing payments are expected to be in the $2 billion range and FirstNet reimbursements are expected to be about $1 billion.

7 Free cash flow is cash from operating activities minus capital expenditures. Due to high variability and difficulty in predicting items that impact cash from operating activities and capital expenditures, the company is not able to provide a reconciliation between projected free cash flow and the most comparable GAAP metric without unreasonable effort.

8 Free cash flow total dividend payout ratio is total dividends paid divided by free cash flow. For full-year 2020, dividends paid totaled $15.0 billion.

Fletcher Cook

AT&T Corporate Communications

Phone: (214) 912-8541

Email: [email protected]

Daphne Avila

AT&T Corporate Communications

Phone: (972) 266-3866

Email: [email protected]

KEYWORDS: Texas United States North America Canada

INDUSTRY KEYWORDS: Technology Mobile/Wireless Internet Telecommunications

MEDIA:

Logo
Logo

Facedrive’s TraceSCAN Achieves Co-Sell Ready Status with Microsoft

Facedrive’s TraceSCAN Achieves Co-Sell Ready Status with Microsoft

TORONTO–(BUSINESS WIRE)–
Facedrive Inc. (“Facedrive”) (TSXV:FD) (OTCQX:FDVRF), a Canadian “people-and-planet first” tech ecosystem is pleased to announce that its contact-tracing platform TraceSCAN has achieved co-sell ready status on the Microsoft Partner Network. Achieving ‘co-sell ready’ status will provide Facedrive TraceSCAN with a significant scaling opportunity by gaining access to Microsoft global customer and partner base. Furthermore, ‘co-sell ready’ status will enable Facedrive and Microsoft teams to collaborate globally on promoting TraceSCAN as a holistic connected health solution powered by Microsoft Azure technology stack. Specifically, Microsoft sales and consulting teams will be able to offer TraceSCAN contact-tracing to their corporate customers as an integrated feature within the enterprise business applications powered by Microsoft products. The greater choice and flexibility provided by being part of the Microsoft Partner’s Network will provide Facedrive TraceSCAN customers with a richer set of options in implementing their contact tracing programs.

Prior to this on November 19, 2020, Facedrive had announced its decision to migrate TraceSCAN to the Microsoft Azure platform https://facedrive.com/press-release/facedrives-tracescan-to-offer-global-contact-tracing-services-powered-by-microsoft-azure/ and its intention to collaborate with Microsoft in offering businesses and individuals around the world easy access to TraceSCAN’s wearable contact-tracing solution.

The TraceSCAN contact-tracing wearable solution, developed jointly by Facedrive Health and a group of researchers from the University of Waterloo, is powered by cutting-edge Bluetooth technology enabling it to work as a standalone device or in conjunction with mobile-powered solutions such as the Government of Canada’s COVID Alert app. TraceSCAN is especially suited for work environments where employees may not be able to carry or have access to mobile devices. The technology also caters to at-risk consumer demographics such as the elderly and low-income individuals and families who may not possess smart phones, have affordable access to data or be familiar with the use of smart phone apps. The TraceSCAN technology is validated by a white paper on privacy and security features issued jointly by Facedrive Health and McCarthy Tétrault’s MT Ventures. Following numerous successful implementations with large enterprise customers such as LiUNA and Air Canada, Waywayseecappo First Nation community, SMEs, and a spiking demand for multifunctional connected health solutions, TraceSCAN has rapidly expanded its use case scenarios into multiple business sectors such as recreation, travel, manufacturing, food processing, construction and other industries.

Apart from co-sell opportunities, Facedrive has already begun to realize the benefits of Microsoft Azure by gaining access to the largest cloud footprint available today, along with data sovereignty, hybrid capabilities, and advanced developer and data services. In addition, Facedrive and Microsoft are exploring synergies in supplying hardware for TraceSCAN enterprise customers, as well as planning to integrate TraceSCAN with IoT Hub, IoT Central, Azure Sphere and other potential fits to leverage advanced workloads within Azure and connect contact-tracing data with business processes and analytics. More collaboration avenues may open through Microsoft’s extensive partner network as the relationship evolves, thus increasing reach of the TraceSCAN products tremendously.

“As an ESG focused technology platform, we are very focused on helping individuals, businesses and economies overcome this pandemic with more confidence and peace of mind. Becoming a co-sell partner with Microsoft increases our reach and distribution ability tremendously and also allows us to build more customized contact-tracing solutions for our clients by combining the technologies and expertise of our respective organizations,” said Sayan Navaratnam, CEO and Chairman of Facedrive. “We are excited that our collaboration with Microsoft has moved forward so quickly as it will help us provide more value to the safety, health and well-being of thousands, if not millions of workers and their families as businesses return to work in these unprecedented circumstances.”

About Facedrive

Facedrive is a multi-faceted “people-and-planet first” tech ecosystem offering socially-responsible services to local communities with a strong commitment to doing business fairly, equitably and sustainably. As part of this commitment, Facedrive’s vision is to fulfil its mandate through a number of verticals that either leverage existing technologies of the Company or project synergies with existing lines of business (the “Facedrive Verticals”). The Facedrive Verticals include its rideshare business (“Facedrive Rideshare”), sustainable e-commerce platform (“Facedrive Marketplace”), food-delivery service (“Facedrive Foods”), e-social platform (“Facedrive Social”) andits contact-tracing and health services business (“Facedrive Health”).

Facedrive Rideshare was among the first to offer a wide variety of environmentally and socially responsible solutions in the Transportation as a Service (TaaS) space, planting thousands of trees based on user consumption and offering choices between electric, hybrid and conventional vehicles (including, more recently, electric and hybrid vehicles on a subscription basis through Steer). Facedrive Marketplace offers curated merchandise created from sustainably sourced materials. Facedrive Foods offers contactless delivery of a wide variety of foods right to consumers’ doorsteps, with a focus on doing so in a socially and environmentally-conscious manner. Facedrive Social strives to keep people connected in a physically-distanced world through its HiQ and other e-socialization platforms that invite users to interact based on common interests and by offering gamification and mutual community support features. Facedrive Health strives to develop and offer innovative technological solutions to the most acute health challenges including its proprietary TraceSCAN wearable technology for contact tracing. Facedrive envisions changing the ridesharing, food delivery, e-commerce, social and health tech narratives for the better, for everyone, and is currently operational in Canada and the United States.

For more about Facedrive, visit www.facedrive.com.

Facedrive Inc.

100 Consilium Pl, Unit 104, Scarborough, ON, Canada M1H 3E3

www.facedrive.com

Forward-Looking Statements

Certain information in this press release contains forward-looking information. This information is based on management’s reasonable assumptions and beliefs in light of the information currently available to us and are made as of the date of this press release. Actual results and the timing of events (for example, those arising from “co-sell ready” status) may differ materially from those anticipated in the forward-looking information as a result of various factors. Information regarding our expectations of future results, performance, achievements, prospects or opportunities or the markets in which we operate is forward-looking information. Statements containing forward-looking information are not facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances. Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements.

See “Forward-Looking Information” and “Risk Factors” in the Corporation’s Filing Statement dated August 28, 2019 for a discussion of the uncertainties, risks and assumptions associated with these statements. Readers are urged to consider the uncertainties, risks and assumptions carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information. We have no intention and undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191205005428/en/

Media: Sana Srithas | [email protected]

Sayan Navaratnam

Chief Executive Officer and Director

Tel: 1-888-300-2228

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Software Internet Environment Public Transport Technology Food/Beverage Transport Retail

MEDIA:

Logo
Logo

CACI Announces $500 Million Accelerated Stock Repurchase Agreement

CACI Announces $500 Million Accelerated Stock Repurchase Agreement

ARLINGTON, Va.–(BUSINESS WIRE)–
CACI International Inc (NYSE: CACI), a leading provider of expertise and technology to government enterprise and mission customers, announced today that, under its previously announced $500 million accelerated share repurchase (ASR) authorization, the company has entered into an accelerated share repurchase agreement to repurchase $500 million of common stock. This equates to approximately 2.1 million shares, at the closing price on March 11, 2021, representing approximately 8% of CACI’s outstanding common stock. On March 16, 2021, CACI will receive an initial delivery of approximately 1.7 million shares with the final number of shares to be repurchased under the ASR based on the average of the daily volume-weighted average prices of CACI common stock during the repurchase period, less a discount and subject to adjustments pursuant to the terms of the ASR agreement. The company anticipates that all repurchases under the ASR will be completed before the end of the fourth quarter of calendar year 2021.

CACI expects to have ample financial capacity to sustain internal investments that enhance growth, innovation, and differentiation, continue its strategic M&A program, execute additional opportunistic share repurchases, or utilize other capital allocation strategies in addition to completing the $500 million ASR.

John Mengucci, CACI’s President and CEO, said, “This accelerated share repurchase transaction is the next step in a more opportunistic and flexible capital deployment strategy and demonstrates our confidence in CACI’s strategy and future growth prospects. It also reflects our commitment to deliver value to our shareholders.”

About CACI

CACI’s approximately 23,000 talented employees are vigilant in providing the unique expertise and distinctive technology that address our customers’ greatest enterprise and mission challenges. Our culture of good character, innovation, and excellence drives our success and earns us recognition as a Fortune World’s Most Admired Company. As a member of the Fortune 1000 Largest Companies, the Russell 1000 Index, and the S&P MidCap 400 Index, we consistently deliver strong shareholder value. Visit us at www.caci.com.

There are statements made herein that do not address historical facts and, therefore, could be interpreted to be forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to risk factors that could cause actual results to be materially different from anticipated results. These risk factors include, but are not limited to, the following: our reliance on U.S. government contracts, which includes general risk around the government contract procurement process (such as bid protest, small business set asides, loss of work due to organizational conflicts of interest, etc.) and termination risks; significant delays or reductions in appropriations for our programs and broader changes in U.S. government funding and spending patterns; legislation that amends or changes discretionary spending levels or budget priorities, such as for homeland security or to address global pandemics like COVID-19; legal, regulatory, and political change from successive presidential administrations that could result in economic uncertainty; changes in U.S. federal agencies, current agreements with other nations, foreign events, or any other events which may affect the global economy, including the impact of global pandemics like COVID-19; the results of government audits and reviews conducted by the Defense Contract Audit Agency, the Defense Contract Management Agency, or other governmental entities with cognizant oversight; competitive factors such as pricing pressures and/or competition to hire and retain employees (particularly those with security clearances); failure to achieve contract awards in connection with re-competes for present business and/or competition for new business; regional and national economic conditions in the United States and globally, including but not limited to: terrorist activities or war, changes in interest rates, currency fluctuations, significant fluctuations in the equity markets, and market speculation regarding our continued independence; our ability to meet contractual performance obligations, including technologically complex obligations dependent on factors not wholly within our control; limited access to certain facilities required for us to perform our work, including during a global pandemic like COVID-19; changes in tax law, the interpretation of associated rules and regulations, or any other events impacting our effective tax rate; changes in technology; the potential impact of the announcement or consummation of a proposed transaction and our ability to successfully integrate the operations of our recent and any future acquisitions; our ability to achieve the objectives of near term or long-term business plans; the effects of health epidemics, pandemics and similar outbreaks may have material adverse effects on our business, financial position, results of operations and/or cash flows; and other risks described in our Securities and Exchange Commission filings.

Corporate Communications and Media:

Jody Brown, Executive Vice President, Public Relations

(703) 841-7801, [email protected]

Investor Relations:

Dan Leckburg, Senior Vice President, Investor Relations

(703) 841-7666, [email protected]

KEYWORDS: Virginia United States North America

INDUSTRY KEYWORDS: Technology Other Defense Contracts Security Other Technology Aerospace Software Manufacturing Networks Defense

MEDIA:

Washington Federal, Inc. Announces Final Results of Tender Offer

Washington Federal, Inc. Announces Final Results of Tender Offer

SEATTLE–(BUSINESS WIRE)–
Washington Federal, Inc. (NASDAQ: WAFD) (“Washington Federal” or the “Company”) announced today the final results of its modified “Dutch auction” tender offer to purchase up to $290 million of its common stock for cash at a price per share not less than $26.50 and not greater than $31.00, which expired at 12:00 midnight, New York City time, at the end of the day on March 9, 2021.

Based on the final count by American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, a total of 1,715,335 shares of Washington Federal’s common stock, $1.00 par value per share, were properly tendered at or below the purchase price of $31.00 per share and neither properly withdrawn nor tendered conditionally by stockholder with conditions that were not met.

Washington Federal has accepted for purchase 1,715,335 shares of its common stock, $1.00 par value per share, at a price of $31.00 per share, for an aggregate cost of approximately $53,175,385.00, excluding fees and expenses related to the tender offer. These shares represent approximately 2.26 percent of the shares outstanding as of March 11, 2021.

American Stock Transfer & Trust Company, LLC will promptly issue payment for the shares of Washington Federal common stock validly tendered and accepted for purchase in the tender offer.

The Company may, in the future, decide to purchase additional shares in the open market subject to market conditions and private transactions, tender offers or otherwise subject to applicable law. Any such purchases may be on the same terms as, or on terms that are more or less favorable to stockholders than, the terms of the offer. Whether the Company makes additional repurchases in the future will depend on many factors, including but not limited to its business and financial performance, the business and market conditions at the time, including the price of the shares, and other factors the Company considers relevant.

The information in this press release describing the tender offer is for informational purposes only and does not constitute an offer to buy or the solicitation of an offer to sell shares of common stock in the tender offer. Goldman Sachs & Co. LLC acted as dealer manager for the Tender Offer. The tender offer was made only pursuant to the Offer to Purchase and the related materials that the Company filed with the SEC, as amended or supplemented. Stockholders who have questions or would like additional information about the tender offer may contact the information agent for the tender offer, D.F. King & Co., Inc., toll-free at (800) 207-3159.

About Washington Federal

Washington Federal, Inc. (NASDAQ: WAFD) is the parent company of Washington Federal Bank, dba WaFd Bank (“WaFd Bank”), a national bank with business consisting primarily of accepting deposits from the general public and investing these funds in loans of various types, including first lien mortgages on single-family dwellings, construction loans, land acquisition and development loans, loans on multi-family, commercial real estate and other income producing properties, home equity loans and business loans. WaFd Bank also invests in certain United States government and agency obligations and other investments permitted by applicable laws and regulations. As of December 31, 2020, WaFd Bank has 234 branches located in Washington, Oregon, Idaho, Arizona, Utah, Nevada, New Mexico and Texas. Through WaFd Bank’s subsidiaries, Washington Federal is also engaged in insurance brokerage activities.

FORWARD-LOOKING STATEMENTS

The foregoing information should be read in conjunction with the financial statements, notes and other information contained in Washington Federal’s 2020 Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. This press release contains statements about Washington Federal’s future that are not statements of historical fact. These statements are “forward looking statements” for purposes of applicable securities laws, and are based on current information and/or management’s good faith belief as to future events. The words “estimate,” “believe,” “expect,” “anticipate,” “project,” and similar expressions signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance. By their nature, forward-looking statements involve inherent risk and uncertainties, which change over time; and actual performance could differ materially from those anticipated by any forward-looking statements. In particular, any forward-looking statements are subject to risks and uncertainties related to the COVID-19 pandemic and the resulting governmental and societal responses. Washington Federal undertakes no obligation to update or revise any forward-looking statement.

Washington Federal, Inc.

425 Pike Street, Seattle, WA 98101

Brad Goode, SVP, Chief Marketing Officer

206-626-8178

[email protected]

KEYWORDS: United States North America Idaho Oregon Washington Utah New Mexico Texas Arizona Nevada

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo

Baxter Announces U.S. FDA 510(k) Clearance of AK 98 Hemodialysis Machine

Baxter Announces U.S. FDA 510(k) Clearance of AK 98 Hemodialysis Machine

  • Latest technology offers a compact, portable and easy-to-use system for dialysis providers
  • Includes two-way connectivity to securely transfer prescription and treatment data
  • Can be used alongside Theranova, Baxter’s novel dialysis membrane

DEERFIELD, Ill.–(BUSINESS WIRE)–
Baxter International Inc. (NYSE:BAX), a global innovator in renal care, today announced U.S. Food and Drug Administration (FDA) clearance of its next-generation Artificial Kidney 98 (AK 98)dialysis machine, which is designed to be a portable and easy-to-use system to administer hemodialysis (HD) treatments. AK 98 offers encrypted, two-way connectivity, which enables the system to pull prescriptions directly from the electronic medical record (EMR) for simplified workflow and data handling.

“We designed this latest version of our AK 98 system to help dialysis providers minimize the operational challenges that can come with administering multiple hemodialysis sessions per machine per day,” said Gavin Campbell, general manager of Baxter’s U.S. Renal Care business. “With our recent De Novo authorization of Theranova, our novel dialysis membrane, our latest innovations to support HD provide our customers with choices for therapy and treatment modality.”

Due to kidney failure, people with end-stage renal disease retain harmful toxins in their blood. During HD therapy, blood is passed through a dialyzer, which acts as the artificial kidney to filter toxins from the blood. AK 98 offers several key features to help dialysis providers efficiently manage HD treatment sessions across chronic dialysis and hospital care environments, including:

  • Automatic Alert Resolution, which enables the machine to self-clear already corrected pressure alarms and avoid unnecessary stoppage of treatment due to brief pressure fluctuations often related to patient movement. This helps streamline patient management by limiting direct exposure and number of redundant device interventions.
  • An intuitive, customizable user interface with app-like functionality designed to simplify prescription management and treatment supervision.
  • A fast, simple set-up process that can be completed by a technician or nurse, allowing for greater flexibility and utilization of staff time and resources.
  • A stable base design that allows for easy concentrate or portable reverse osmosis (RO) storage and transport with the machine.

AK 98 is a proven dialysis platform that builds on Baxter’s longstanding tradition of pioneering and delivering groundbreaking advancements in the HD space. AK 98 is currently used in more than 90 countries globally and will be available in the U.S. in the coming weeks. More information is available at https://hemodialysis.baxter.com/ak98.

About Baxter

Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.

Rx Only. For safe and proper use of this device, refer to the full Instructions for Use.

The AK 98 dialysis machine is intended to be used for intermittent hemodialysis and/or isolated ultrafiltration treatments of patients with chronic or acute renal failure or fluid overload upon prescription by a physician.

The AK 98 dialysis machine is indicated to be used on patients with a body weight of 25kg or more.

The AK 98 dialysis machine is intended to be used by trained operators when prescribed by a physician, in a chronic care dialysis or hospital care environment.

The AK 98 dialysis machine is not intended for selfcare or home use.

The Theranova Dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis. It provides an expanded solute removal profile with increased removal of various middle molecules (up to 45 kDa) that may play a pathologic role in the uremic clinical syndrome. The Theranova Dialyzer is not intended for hemofiltration or hemodiafiltration therapy. The total extracorporeal blood volume for the Theranova Dialyzer and the set should represent less than 10% of the patient’s blood volume.

This release includes forward-looking statements concerning the AK 98 dialysis machine and Theranova, including anticipated availability and potential benefits associated with their use. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply, or patient safety issues (including as a result of a natural disaster, public health crises and epidemics/pandemics, regulatory actions or otherwise); changes in law and regulations; and other risks identified in Baxter’s most recent filing on Form 10-K and 10-Q and other SEC filings, all of which are available on Baxter’s website. Baxter does not undertake to update its forward-looking statements.

Baxter, AK 98 and Theranova are registered trademarks of Baxter International Inc.

Media Contact

Colleen Weber, (224) 948-5353

[email protected]

Investor Contact

Clare Trachtman, (224) 948-3020

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Surgery General Health Health FDA Diabetes Medical Devices

MEDIA: